October 23, 2019
Alexion ends third quarter 2019 with 23% increase in total revenues
Alexion finished the third quarter 2019 with total revenues of $1,263.1 million, which represents a 23% increase over 3the same…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Alexion Pharmaceuticals
July 3, 2019
ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from European Commission for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
– ULTOMIRIS has the potential to become the new standard of care for both complement inhibitor-naïve patients and patients switching from SOLIRIS® (eculizumab) –
March 20, 2019
Alexion and Zealand Pharma Announce Collaboration to Discover and Develop Peptide Therapies for Complement-Mediated Diseases
BOSTON & COPENHAGEN, Denmark–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Zealand Pharma A/S (NASDAQ:ZEAL) today announced a collaboration to discover and…
February 5, 2018
Alexion Pharmaceuticals welcomes new board member from data and analytics company
Alexion Pharmaceuticals has adde Judith A. Reinsdorf to its Board of Directors.
January 23, 2018
Alexion Pharmaceuticals refreshes its board of directors
Alexion Pharmaceuticals has welcomed Deborah Dunsire, M.D. as the company’s Board of Directors new independent director.
June 1, 2017
Alexion names several new executives
Alexion Pharmaceuticals has named several leading chairs to its executive leadership team that will be effective from June 5, 2017.
May 23, 2017
Alexion Pharmaceuticals welcomes new CCO, makes other managerial changes
Alexion Pharmaceuticals has announced big changes to its executive leadership team. Brian Goff is joining Alexion as Chief Commercial Officer, effective June 1, 2017.
March 27, 2017
Alexion Pharmaceutical name new CEO
Alexion Pharmaceuticals’s Board of Directors has appointed Ludwig N. Hantson, Ph.D., as Chief Executive Officer and member of the Board of Directors, to succeed David R. Brennan, who has led the company as Interim CEO since December 2016.
March 8, 2017
Alexion waits for FDA’s OK for generalized myasthenia gravis drug
U.S. Food and Drug Administration(FDA) has accepted for review the Alexion Pharmaceuticals’s supplemental Biologics License Application (sBLA) to extend the indication for Soliris (eculizumab) as a potential treatment for patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.
March 3, 2017
Alexion Pharmaceuticals’s founder retires as Chairman of the Board, current CEO to succeed him
Leonard Bell, founder of Alexion Pharmaceuticals will not stand for reelection as a Board member and will retire as Chairman of the Board and as a Director at the end of his term, effective as of the Annual Meeting of Shareholders scheduled for May 10, 2017.